News | Drug-Eluting Balloons | June 19, 2020

iVascular Launches Essential Pro Coronary Drug-coated Balloon

iVascular Launches Essential Pro Coronary Drug-coated Balloon

June 19, 2020 — iVascular SLU announced the global launch of Essential Pro, a novel coronary artery drug-coated balloon (DCB).

The Essential Pro DCB presents several platform improvements from its predecessor such as:
    • Superior safety with fast deflation times due to an increase of the inflation channel and the availability of two different shafts.
    • Better pushability due to an improved transition lumen structure that transmits the whole push to the distal shaft, and uniform transmission due to a new straight distal dual layer shaft design without welds.
    • Improved visibility with metallic radiopaque markers.
    • Improved trackability due to Hydrax plus, iVascular proprietary hydrophilic coating technology. Hydrax plus is applied in the distal shaft, reducing friction during navigation.

The Eessential Pro is indicated for the dilatation of stenosis or coronary artery or bypass grafts occlusions, including small vessels, as well as for residual stenosis after treatment with balloon or endoprosthesis and pre- and post-dilation of coronary endovascular prosthesis.
 

Clinical Study in Small Vessels Using Drug-coated Balloon

An observational, prospective and multicenter registry in small vessels. Baseline characteristics showed a very small diameter of reference (<2.5mm) and high-risk patients (56% diabetics) with only a 12.7% of bailout stenting. In this registry, essential shows a 4.2% TLF at 12-months as a primary endpoint and 9.9% MACE at 12-month as a secondary endpoint. essential demonstrates to be a reliable alternative for small coronary vessels.[1]

Essential DCB Use in Stent Restenosis

An investigator initiated, observational, prospective and multicenter study. DES restenosis was treated in 67% of the cases and a 94% of DCB angiographic success was achieved with only 2 additional stenting. In this study essential shows a 51.4% In-segment maximal area stenosis at 6-month as a primary endpoint and a 13.3% TLF at 24-month as a secondary endpoint. In this study, essential showed a good and sustained efficacy in the treatment of ISR (mostly of DES) maintained on the very long-term.[2]
 
 
For more information: ivascular.global/coronary/essentialpro/
 

References:

1. Rosa Alba Abellas-Sequeiros, Rodés-Cabau J., et al. Percutaneous Coronary Intervention for Treating De-Novo Lesions in Small Coronary Vessels: Initial Experience With the Essential Paclitaxel-Coated Balloon. Coronary Artery Disease. 29(6):477 481, September 2018.

2. J. De La Torre Hernández. Angiography and Optical Coherence Tomography Assessment of the Drug-Coated Balloon ESSENTIAL for the Treatment of In-Stent Restenosis. Cardiovasc Revasc Med. 2019 Jul 23. pii: S1553-8389(19)30433-6.

 
 

Related Content

News | Cath Lab | July 06, 2020
July 6, 2020 — Black patients who undergo percutaneous coronary intervention (PCI) are at an increased risk for major
TCT cancels in-person meeting and goes virtual due to COVID-19
News | Cath Lab | May 27, 2020
May 27, 2020 — To ensure the health and safety of all attendees due to the ongoing COVID-19 (SARS-CoV-2) pandemic, th
Patients undergoing cardiac catheterization are traditionally instructed to follow nothing by mouth, or nil per os (NPO), as there are no current standardized fasting protocols, but the CHOWNOW study found patients do not need to fast and will have similar outcomes. #SCAI2020
Feature | Cath Lab | May 18, 2020
May 18, 2020 – Patients undergoing cardiac catheterization are traditionally instructed to follow nothing by mouth, o
Ehtisham Mahmud, M.D., FSCAI, president of the Society for Cardiovascular Angiography and Interventions (SCAI) and chief, Division of Cardiovascular Medicine at UC San Diego Medical Center,
Podcast | Cath Lab | May 13, 2020
This podcast is an interview with Ehtisham Mahmud, M.D., FSCAI, president of the Society for Cardiovascular Angiograp
Nuance Communications Inc. introduced Nuance Cardiovascular CAPD, a new computer-assisted physician documentation (CAPD) solution designed to help cardiologists improve the quality of complex documentation and the accuracy of reimbursement for cardiac catheterization procedures. The Nuance Cardiovascular CAPD solution is available through a partnership with ZHealth for this solution, which is based on patented algorithms built with ZHealth’s interventional documentation and coding expertise.
News | Cath Lab | January 31, 2020
January 29, 2020 – Nuance Communications Inc.
Videos | Cath Lab | January 09, 2020
Haval Chweich, M.D., medical director of the cardiac critical care unit (CCU) at Tufts Medical Center, and assistant...